JLL Partners poised for 60-plus-pct IRR on Patheon exit

15 May 2017•2 mins read
JLL Partners, Patheon NV, Thermo Fisher Scientific, healthcare, private equity, merger, M&A
LinkedInXEmail
LinkedInXEmail